Pfizer offers EU contract extension with reduced covid-19 vaccine doses, payment for unused vaccines


(MENAFN) According to a recent report from the Financial Times, Pfizer has proposed to extend its contract with the European Union for its COVID-19 vaccine, but with a 40% reduction in doses supplied and delivery delays. While this proposal has faced objections from some EU member states, Pfizer has insisted that it be paid for the full number of doses originally agreed upon, even though many of these doses may never be produced under the new terms.

The contract extension, if agreed upon, would push the vaccine agreement out to 2026. This proposal comes at a time when some countries are experiencing a major supply glut of vaccines, while others continue to face shortages. However, critics argue that the deal would serve the interests of Big Pharma over the interests of European Union citizens.

The full text of the amendments to the vaccine contract has not been made public, but it was reportedly presented by European health commissioner Stella Kyriakides during a closed-door meeting in Brussels on Tuesday. The objections raised by some European Union members suggest that there may be further negotiations and discussions before any agreement is reached.

MENAFN15032023000045014146ID1105783446


MENAFN

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.

Newsletter